Head-To-Head Contrast: Immunovant (NASDAQ:IMVT) vs. Genocea Biosciences (NASDAQ:GNCAQ)

Immunovant (NASDAQ:IMVT) and Genocea Biosciences (NASDAQ:GNCAQ) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Profitability

This table compares Immunovant and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-57.97%	-52.47%
Genocea Biosciences	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings for Immunovant and Genocea Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	0	0	17	0	3.00
Genocea Biosciences	0	0	0	0	N/A

Immunovant presently has a consensus target price of $48.00, suggesting a potential upside of 69.49%.

Risk and Volatility

Immunovant has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.31, meaning that its share price is 131% more volatile than the S&P 500.

Insider & Institutional Ownership

47.1% of Immunovant shares are owned by institutional investors. 4.8% of Immunovant shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Immunovant and Genocea Biosciences’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$210.96 million	($1.84)	-15.39
Genocea Biosciences	$1.64 million	N/A	-$33.20 million	N/A	N/A

Genocea Biosciences has higher revenue and earnings than Immunovant.

Summary

Genocea Biosciences beats Immunovant on 5 of the 8 factors compared between the two stocks.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.